Earnings Call Summary | Durect(DRRX.US) Q2 2024 Earnings Conference
Earnings Call Summary | Durect(DRRX.US) Q2 2024 Earnings Conference
The following is a summary of the DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript:
以下是Durect公司（durect）2024年第二季度業績會交流摘要：
Financial Performance:
金融業績：
DURECT reported Q2 2024 revenues of $2.2 million, compared to $2.1 million in the same quarter last year.
Research and Development expenses decreased to $2.2 million in Q2 2024 from $7.9 million in Q2 2023, reflecting lower clinical trial-related and employee costs.
SG&A expenses were reduced to $3.0 million from $3.8 million due to cost-management measures.
Current cash and investment reserves stand at $15.8 million, sufficient to fund operations through the end of 2024.
Durect在2024年第二季度報告的營收爲220萬美元，去年同季度爲210萬美元。
研發費用由2023年第二季度的790萬美元下降至2024年第二季度的220萬美元，反映出臨床試驗相關和員工費用下降。
由於成本控制措施，SG&A費用從380萬美元降至300萬美元。
目前的現金和投資儲備爲1580萬美元，足以資助到2024年底的經營活動。
Business Progress:
業務進展：
DURECT has made significant advances with larsucosterol, moving towards a confirmatory Phase III clinical trial for alcohol-associated hepatitis (AH).
The FDA has engaged positively with the proposed clinical trial, confirming a single pivotal trial sufficiency for an NDA filing.
Larsucosterol received Breakthrough Therapy designation, enhancing interaction with the FDA.
Durect已經在larsucosterol方面取得了重大進展，正朝着確認用於酒精相關性肝炎（AH）的第三階段臨床試驗邁進。
FDA對擬議的臨床試驗做出了積極的回應，確認單個關鍵試驗就足以提交NDA申請。
Larsucosterol獲得了突破性療法認定，增強了與FDA的互動。
Opportunities:
機會：
Larsucosterol, if successful in Phase III trials, could become the first FDA-approved treatment for AH, addressing an unmet medical need.
The drug's potential market in AH hospitalizations could translate into substantial cost savings for the healthcare system in the U.S.
如果larsucosterol在第三階段臨床試驗中獲得成功，可以成爲針對AH的首個獲得FDA批准的治療方法，解決了一個未被滿足的醫療需要。
這種藥物在AH住院市場上的潛在市場規模可以轉化爲美國醫療保健系統的巨大成本節約。
Risks:
風險：
The expected time line for Phase III trial initiation and completion carries uncertainties, requiring confirmed funding. Gradual progress is anticipated as detailed information and FDA confirmations are pending.
預計第三階段試驗啓動和完成的時間表存在不確定性，需要確認資金。隨着詳細信息和FDA確認的等待，預計將逐步取得進展。
More details: Durect IR
更多詳情：Durect IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。